User:Mr. Ibrahem/Duvelisib
 | |
| Clinical data | |
|---|---|
| Pronunciation | doo-VE-li-SIB |
| Trade names | Copiktra |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618056 |
| License data | |
| Routes of administration | By mouth (capsules) |
| Drug class | PI3-kinase inhibitor[1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | mainly metabolized by CYP3A4[2] |
| Onset of action | 1-2 hours after initial administration |
| Elimination half-life | 5.2 to 10.9 hours |
| Excretion | Feces (79%), urine (14%) |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C22H17ClN6O |
| Molar mass | 416.87 g·mol−1 |
| 3D model (JSmol) | |
| |
Duvelisib, sold under the brand name Copiktra, is a medication used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma.[1] It is used when other treatments have failed.[1] It is taken by mouth.[1]
Common side effects include diarrhea, low blood cells, rash, tiredness, fever, liver problems, and muscle pains.[1] Other serious side effects include inflammation of the lungs, infertility, and infections.[1] Use in pregnancy may harm the baby.[1] It is a dual inhibitor of PI3Kδ and PI3Kγ.[1]
Duvelisib was approved for medical use in the United States in 2018 and Europe in 2021.[1][3] In the United States 4 weeks of treatment costs about 17,200 USD as of 2021.[4]
References
[edit]- ^ a b c d e f g h i j k "Duvelisib Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 28 February 2019. Retrieved 28 February 2019.
- ^ "Full prescribing information: COPIKTRA (duvelisib)" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on 11 February 2020. Retrieved 23 October 2018.
- ^ a b "Copiktra". Archived from the original on 16 December 2021. Retrieved 27 December 2021.
- ^ "Copiktra Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 27 January 2021. Retrieved 27 December 2021.